Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions

Skin biopsy

(2016) Dirk M. Elston et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis

(2015) Omar Abdel-Rahman et al.   Future Oncology

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Acute skin reaction suggestive of pembrolizumab-induced radiosensitization

(2015) Vincent Sibaud et al.   MELANOMA RESEARCH

A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab

(2015) Giuliana Carlos et al.   MELANOMA RESEARCH

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

(2015) Martina Sanlorenzo et al.   JAMA Dermatology

Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an “Innocent Bystander”

(2014) Lucia Gelao et al.   Toxins

RETRACTED: Bullous pemphigoid: Associations and management guidelines

(2013) Eleonora Ruocco et al.   CLINICS IN DERMATOLOGY

Bullous pemphigoid: Etiology, pathogenesis, and inducing factors: Facts and controversies

(2013) Ada Lo Schiavo et al.   CLINICS IN DERMATOLOGY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE